Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib versus temsirolimus in relapsed or refractory mantle cell lymphoma
NL-OMON40109Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Jul 2013; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON40109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40109.